NEWS Glass Expansion Newsletter | October 2016 | Issue 41 Glass Expansion News APPLICATION SPOTLIGHT MicroMist Nebulizer for Single Cell Mass Cytometry Noel Caseya, Adeeb Rahmanb, Ryan Brennanc and Jerry Duludec a. Atomic Spectroscopy Consultant, Watertown, MA 02472. noelcasey@gmail.com b. Director of Technology Development, Human Immune Monitoring Core, Icahn School of Medicine at Mt. Sinai, New York, NY 10029. adeeb.rahman@mssm.edu c. Glass Expansion Inc. Pocasset, MA 02559. geusa@geicp.com Introduction Mass cytometry is the current state-of-the-art technology in single cell-analysis that is transforming the fields of immunology, cancer biology, vaccine development, drug discovery, and translational medicine(1-6). This new tool is providing scientists with the most detailed overview of normal and diseased cells and how they respond to various drug treatment options. The technology was developed at the University of Toronto and commercialized by DVS Sciences Inc. in 2009 before being acquired by Fluidigm Corp in 2014. Since its introduction, three generations of instruments have been released (CyTOF, CyTOF2 and Helios) and the number of publications utilizing mass cytometry has nearly doubled every 2 years. Mass Cytometry combines the elemental quantitation, specificity and dynamic range of Inductively Coupled Plasma Time of Flight Mass Spectrometry (ICP-TOF-MS) with the single cell analysis capabilities of traditional fluorescence-based flow cytometry to study, diagnose and develop treatments for diseases. The number of parameters that can be simultaneously measured on single cells by traditional flow cytometry is restricted by a limited range of available fluorochromes, spectral overlap between fluorochromes and intrinsic cellular autofluoresence. Mass cytometry uses enriched stable isotope metals attached to antibodies using metal-chelating reagents to label specific protein biomarkers in cells from blood, tissues, or cell cultures, with minimal mass spectral overlap between each metal tag. The mass cytometer measures the expression of these biomarkers in each individual cell according to the type and concentration of each metal detected. The latest generation of instrument provides more than 120 detection channels at typical acquisition rates of up to 500 cells/second(7). The primary sample introduction challenge facing Mass Cytometry is that its acquisition rate is ~10 times slower than conventional flow cytometers. So using a robust and reliable sample introduction system that maximizes the numbers of intact single cells entering the ICP while maintaining instrument detection limits is key. Glass Expansion’s latest research addresses factors that can affect cell integrity prior to introduction to the ICP and ways to improve the efficiency and reliability of sample transport in Mass Cytometry. A newly designed MicroMistTM concentric nebulizer with a zero dead volume capillary connection is evaluated in addition to a tool to accurately monitor sample delivery. New Sales & Marketing Manager Glyn Russell has taken up the position of Sales & Marketing Manager at Glass Expansion’s Australian head office. Glyn has extensive experience in the analytical equipment industry and is particularly knowledgeable regarding ICP instrumentation. He will continue to enhance Glass Expansion’s reputation for highest quality products and customer support. He replaces Peter Liddell who has retired. In this issue: • Application Spotlight................1 – 5 • GE News..........................................1 • New Products..................................6 WindTunnel Mobile Cart • Instrument News.............................7 From Agilent From Analytik Jena From Horiba Jobin Yvon www.geicp.com 1
GE Newsletter October 2016
To see the actual publication please follow the link above